Rockville, MD, United States of America

Bridget A Cooksey

USPTO Granted Patents = 3 

 

 

Average Co-Inventor Count = 5.0

ph-index = 3

Forward Citations = 72(Granted Patents)


Location History:

  • Gaithersburg, MD (US) (2013)
  • Rockville, MD (US) (2012 - 2014)

Company Filing History:


Years Active: 2012-2014

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Bridget A. Cooksey in Biopharmaceuticals

Introduction: Bridget A. Cooksey, an accomplished inventor based in Rockville, MD, has made significant strides in the field of biopharmaceuticals. With a total of three patents credited to her name, Cooksey's work focuses on humanized antibodies aimed at addressing various health conditions, showcasing her pioneering spirit in medical innovation.

Latest Patents: Among Bridget A. Cooksey's notable patents are two groundbreaking inventions related to humanized antibodies. The first patent involves humanized antibodies against TL1A, which specifically bind to TNF superfamily member 15 (TNFSF15), also known as TL1A. These antibodies are designed to function as antagonists and may be employed in the treatment or diagnosis of conditions associated with TL1A function. The second patent pertains to humanized antibodies against LIGHT, directed at antigen-binding polypeptides that specifically target the LIGHT polypeptide. This invention outlines methods for utilizing such antibodies in the treatment or diagnosis of various immune, inflammatory, and malignant diseases, including inflammatory bowel disease, Crohn’s disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis, and transplantation.

Career Highlights: Bridget A. Cooksey is currently a part of Teva Biopharmaceuticals USA, Inc., where she continues to innovate and develop therapeutic solutions. Her career reflects a dedication to advancing medical science through the discovery and application of new treatments, particularly in the realm of antibody therapies.

Collaborations: Throughout her career, Cooksey has had the privilege of collaborating with esteemed colleagues, including Rodger G. Smith and Palanisamy Kanakaraj. These collaborations enrich her research and enhance the potential impact of her inventions on the biomedical field.

Conclusion: Bridget A. Cooksey exemplifies the role of an innovative inventor in the biopharmaceutical sector. Her work on humanized antibodies holds promise for improving the diagnosis and treatment of various medical conditions, further establishing her as a key contributor to advancements in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…